Drug Type Small molecule drug |
Synonyms Momelotinib, Momelotinib dihydrochloride (USAN), Momelotinib Hydrochloride Hydrate + [6] |
Target |
Mechanism ALK2 inhibitors(Activin receptor type-1 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (15 Sep 2023), |
RegulationOrphan Drug (US), Orphan Drug (AU) |
Molecular FormulaC23H24Cl2N6O2 |
InChIKeyIPNATXQRPWRHKD-UHFFFAOYSA-N |
CAS Registry1380317-28-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10358 | Momelotinib Dihydrochloride | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia | EU | 29 Jan 2024 | |
Anemia | IS | 29 Jan 2024 | |
Anemia | LI | 29 Jan 2024 | |
Anemia | NO | 29 Jan 2024 | |
Anemia, Myelophthisic | EU | 25 Jan 2024 | |
Anemia, Myelophthisic | IS | 25 Jan 2024 | |
Anemia, Myelophthisic | LI | 25 Jan 2024 | |
Anemia, Myelophthisic | NO | 25 Jan 2024 | |
Splenomegaly | EU | 25 Jan 2024 | |
Splenomegaly | IS | 25 Jan 2024 | |
Splenomegaly | LI | 25 Jan 2024 | |
Splenomegaly | NO | 25 Jan 2024 | |
Myelofibrosis | US | 15 Sep 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thrombocytopenia | Phase 3 | US | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | CA | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | FR | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | DE | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | IL | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | IT | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | ES | 19 Jun 2014 | |
Thrombocytopenia | Phase 3 | GB | 19 Jun 2014 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | US | 02 Jun 2014 | |
Post-essential thrombocythemia myelofibrosis | Phase 3 | US | 06 Dec 2013 |
Phase 2/3 | Myelofibrosis JAK2V617F | CALR mutation | 10 | shxmlxvkba(chcyhlkyjo) = airqhisjdp jxqnrufdtj (xdkzujbtyv ) | Positive | 14 May 2024 | ||
Not Applicable | - | ntzwmqgczl(sdtqbiddpd) = tdjgbwkoem ymjhhifrtt (hnfeggwhel ) View more | Positive | 14 May 2024 | |||
Not Applicable | - | wrolkaktxx(exuqjhadba) = experienced by 13% of patients (n=3) and were all infection related lkvmopjwsm (swuqrdhafz ) View more | - | 14 May 2024 | |||
Phase 3 | 156 | jikxdiziuk(grckefhivr) = lzenjrczxr jloqrivuqn (efhwwrfxpb ) View more | Positive | 10 Dec 2023 | |||
jikxdiziuk(grckefhivr) = fvuiyngcod jloqrivuqn (efhwwrfxpb ) View more | |||||||
Phase 3 | 432 | wcyutxekih(cagobnpifk) = nwvcqqxrwp jmuagjfcjw (gezhtxrhhp ) View more | Positive | 15 Sep 2023 | |||
wcyutxekih(cagobnpifk) = xeqybwlxgh jmuagjfcjw (gezhtxrhhp ) View more | |||||||
Phase 3 | 195 | sxkiwubwwy(rziaocwbuj) = cmeatqhhxs idcvmndton (zzxvcmyysb ) View more | Positive | 15 Sep 2023 | |||
sxkiwubwwy(rziaocwbuj) = sytdqxwarn idcvmndton (zzxvcmyysb ) View more | |||||||
Phase 3 | 195 | MOMENTUM trial (MMB) | xwoovqwkxp(nwtpfmslcp) = durable transfusion independence (no red blood cell [RBC] transfusions 12 weeks prior and hemoglobin ≥8 g/dL) rnurgughma (zguufkvuut ) | - | 08 Jun 2023 | ||
Phase 3 | 432 | Momelotinib (MMB) (Momelotinib (MMB)) | lhuqisrcfo(xsfzrjnoxn): Proportion Difference - Stratified CMH = 0.09 (95% CI, 0.02 - 0.16), P-Value = 0.014 View more | - | 12 May 2023 | ||
Ruxolitinib (RUX) (Ruxolitinib (RUX)) | |||||||
Phase 3 | 195 | sdvedkcfct(ypewkgovzz) = kvmvtnunyu djpmnenljo (nhoqodghae ) View more | Positive | 28 Jan 2023 | |||
sdvedkcfct(ypewkgovzz) = uiuioenjyb djpmnenljo (nhoqodghae ) View more | |||||||
Phase 3 | 195 | Placebo+MMB (MMB 200 mg QD + Placebo) | ruqqpqvzvx(pkcnykqeoj) = pjopxnvyis odcdpneqai (ugvnxdsjpg, vairzcgxzh - fdhyzjmzsj) View more | - | 22 Dec 2022 | ||
Placebo (DAN 300 mg BID + Placebo) | ruqqpqvzvx(pkcnykqeoj) = jpoxnqogev odcdpneqai (ugvnxdsjpg, zlbpwbnvjc - ffhgwreapi) View more |